Citi Upgrades Anthera Pharma (ANTH) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Anthera Pharmaceuticals Reports 2015 First Quarter and Operational Update
May 11, 2015 5:30 PM EDTCompleted Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering Received $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Phase 3 Development of Sollpura (liprotamase)
HAYWARD, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced financial results and an operational update for the first quarter ended March 31, 2015.
Net loss for the quarter ended March 31, 2015 was $7.7 million, compared to... More
